TREM2 and amyloidosis: It has also been demonstrated in the 5XFAD model of AD that constitutive deletion of Rev-erbα (a circadian clock component and known as heme-responsive nuclear receptor protein) decreased amyloid plaque number and size and prevented plaque-associated amplification of disease-associated microglia markers, including Triggering Receptor Expressed On Myeloid Cells 2 (TREM2), lymphocyte common antigen (CD45) and C-Type Lectin Domain Containing 7A (Clec7a) [77].